These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 25609634)

  • 1. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
    May PC; Willis BA; Lowe SL; Dean RA; Monk SA; Cocke PJ; Audia JE; Boggs LN; Borders AR; Brier RA; Calligaro DO; Day TA; Ereshefsky L; Erickson JA; Gevorkyan H; Gonzales CR; James DE; Jhee SS; Komjathy SF; Li L; Lindstrom TD; Mathes BM; Martényi F; Sheehan SM; Stout SL; Timm DE; Vaught GM; Watson BM; Winneroski LL; Yang Z; Mergott DJ
    J Neurosci; 2015 Jan; 35(3):1199-210. PubMed ID: 25609634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from a BACE1 inhibitor trial: off-site but not off base.
    Lahiri DK; Maloney B; Long JM; Greig NH
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S411-9. PubMed ID: 24530026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice.
    Dekeryte R; Franklin Z; Hull C; Croce L; Kamli-Salino S; Helk O; Hoffmann PA; Yang Z; Riedel G; Delibegovic M; Platt B
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166149. PubMed ID: 33892080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
    J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
    Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
    Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
    Barão S; Moechars D; Lichtenthaler SF; De Strooper B
    Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
    Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
    Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
    McKinzie DL; Winneroski LL; Green SJ; Hembre EJ; Erickson JA; Willis BA; Monk SA; Aluise CD; Baker TK; Lopez JE; Hendle J; Beck JP; Brier RA; Boggs LN; Borders AR; Cocke PJ; Garcia-Losada P; Lowe SL; Mathes BM; May PC; Porter WJ; Stout SL; Timm DE; Watson BM; Yang Z; Mergott DJ
    J Med Chem; 2021 Jun; 64(12):8076-8100. PubMed ID: 34081466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BACE1 inhibitors for the treatment of Alzheimer disease].
    Tomita T
    Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
    Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
    J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
    Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
    J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
    Winneroski LL; Erickson JA; Green SJ; Lopez JE; Stout SL; Porter WJ; Timm DE; Audia JE; Barberis M; Beck JP; Boggs LN; Borders AR; Boyer RD; Brier RA; Hembre EJ; Hendle J; Garcia-Losada P; Minguez JM; Mathes BM; May PC; Monk SA; Rankovic Z; Shi Y; Watson BM; Yang Z; Mergott DJ
    Bioorg Med Chem; 2020 Jan; 28(1):115194. PubMed ID: 31786008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
    Jeppsson F; Eketjäll S; Janson J; Karlström S; Gustavsson S; Olsson LL; Radesäter AC; Ploeger B; Cebers G; Kolmodin K; Swahn BM; von Berg S; Bueters T; Fälting J
    J Biol Chem; 2012 Nov; 287(49):41245-57. PubMed ID: 23048024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
    Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
    PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial.
    Koriyama Y; Hori A; Ito H; Yonezawa S; Baba Y; Tanimoto N; Ueno T; Yamamoto S; Yamamoto T; Asada N; Morimoto K; Einaru S; Sakai K; Kanazu T; Matsuda A; Yamaguchi Y; Oguma T; Timmers M; Tritsmans L; Kusakabe KI; Kato A; Sakaguchi G
    J Med Chem; 2021 Feb; 64(4):1873-1888. PubMed ID: 33588527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
    Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
    J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
    Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.